



# Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma

## Citation

Gkatzamanidou, M, P P Sfikakis, S A Kyrtopoulos, C Bamia, M A Dimopoulos, and V L Souliotis. 2014. "Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma." *British Journal of Cancer* 111 (7): 1293-1304. doi:10.1038/bjc.2014.410. <http://dx.doi.org/10.1038/bjc.2014.410>.

## Published Version

doi:10.1038/bjc.2014.410

## Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:22857008>

## Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA>

## Share Your Story

The Harvard community has made this article openly available. Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)

**Keywords:** multiple myeloma; melphalan; epigenetic changes; DNA damage response; transcription-coupled repair; clinical outcome; malignant bone marrow plasma cells; peripheral blood mononuclear cells

# Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma

M Gkatzamanidou<sup>1,2</sup>, P P Sfikakis<sup>3</sup>, S A Kyrtopoulos<sup>4</sup>, C Bamia<sup>5</sup>, M A Dimopoulos<sup>2</sup> and V L Souliotis<sup>\*,4</sup>

<sup>1</sup>Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA; <sup>2</sup>Department of Clinical Therapeutics, University of Athens School of Medicine, 11528 Athens, Greece; <sup>3</sup>First Department of Propedeutic Medicine, University of Athens School of Medicine, 11527 Athens, Greece; <sup>4</sup>Institute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, 48 Vassileos Constantinou Avenue, 11635 Athens, Greece and <sup>5</sup>Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, 11527 Athens, Greece

**Background:** Melphalan is one of the most active chemotherapeutic agents in the treatment of multiple myeloma (MM). However, the mechanism underlying differential patient responses to melphalan therapy is unknown.

**Methods:** Chromatin structure, transcriptional activity and DNA damage response signals were examined following *ex vivo* treatment with melphalan of both malignant bone marrow plasma cells (BMPCs) and peripheral blood mononuclear cells (PBMCs) of MM patients, responders ( $n = 57$ ) or non-responders ( $n = 28$ ) to melphalan therapy. PBMCs from healthy controls ( $n = 25$ ) were also included in the study.

**Results:** In both BMPCs and PBMCs, the local chromatin looseness, transcriptional activity and repair efficiency of the transcribed strand (TS) were significantly higher in non-responders than in responders and lowest in healthy controls (all  $P < 0.05$ ). Moreover, we found that melphalan-induced apoptosis inversely correlated with the repair efficiency of the TS, with the duration of the inhibition of mRNA synthesis, phosphorylation of p53 at serine 15 and apoptosis rates being higher in responders than in non-responders (all  $P < 0.001$ ).

**Conclusions:** Our findings provide a mechanistic basis for the link between DNA repair efficiency and response to melphalan therapy. Interestingly, the observation of these phenomena in PBMCs provides a novel approach for the prediction of response to anti-myeloma therapy.

Multiple myeloma (MM) is the second most commonly diagnosed haematologic malignancy, characterised by proliferation of clonal long-lived plasma cells within the bone marrow and overproduction of monoclonal immunoglobulin in the serum or urine (Chng *et al*, 2007). The disease presents clinically with a broad range of manifestations including skeletal destruction, immune suppression and end-organ sequelae with devastating complications for patients and their quality of life. Since the pioneering work of Barlogie *et al* in the 1980s (Barlogie *et al*, 1986), high-dose melphalan (HDM) followed by autologous stem cell transplantation (ASCT) has been

the gold standard of treatment for young and eligible MM patients and the backbone of treatment for elderly patients or non-eligible transplant MM patients (Giralt, 2010; Cavo *et al*, 2011). Advances in the understanding of biology of the disease and of the bone marrow microenvironment have translated into important therapeutic advances in the past decade (Palumbo and Anderson, 2011). Despite the recent advances in MM therapeutics with development of proteasome inhibitors (bortezomib, carfilzomib), immunomodulatory drugs (thalidomide, lenalidomide, pomalidomide) and novel epigenetic agents (histone deacetylase inhibitors,

\*Correspondence: Dr VL Souliotis; E-mail: vls@eie.gr

Received 31 March 2014; revised 15 May 2014; accepted 30 June 2014; published online 22 July 2014

© 2014 Cancer Research UK. All rights reserved 0007–0920/14

HDACi; San Miguel *et al*, 2008; Redic, 2013) that prolonged the median survival of MM patients to more than 7 years, the disease remains incurable due to the development of resistance and relapse practically in all patients (Anderson, 2012; Kumar *et al*, 2012).

Melphalan is an alkylating agent producing *N*-alkylpurine monoadducts, a small proportion of which goes on to form DNA interstrand cross-links (ICL) that are associated with the agent cytotoxicity (Balcome *et al*, 2004; Edler *et al*, 2006). The repair of DNA damage caused by alkylating agents such as melphalan is an important mechanism of tumour resistance against those agents (Spanswick *et al*, 2002). Melphalan *N*-alkylpurine monoadducts, precursors of ICL, are substrates for both sub-pathways of the nucleotide excision repair (NER), that is, the global genome repair (GGR), which removes DNA damage from the entire genome, and the more specialized transcription-coupled repair (TCR) that removes DNA lesions located in the transcribed strand (TS) (Episkopou *et al*, 2009). TCR is initiated by stalling of the transcription machinery at a DNA lesion, resulting in the recruitment of NER factors that remove the lesion from the DNA. In this fashion, the recovery of transcription after exposure to DNA-damaging agents is ensured, and this generally is considered to be the primary function of TCR (Vermeulen and Foustari, 2013). In case the load of DNA damage exceeds the capacity of TCR or when TCR is impaired, persistently stalled transcription complexes induce apoptosis, averting the generation of mutations in cells following replication (Hendriks *et al*, 2010). On the other hand, ICL repair is characterised by complexity and involves the Fanconi anaemia repair pathway, NER, translesion synthesis and homologous recombination (Thompson and Hinz, 2009; Deans and West, 2011).

In mammalian cells, genomic integrity is maintained by a network of DNA damage response (DDR) mechanisms, initiated by the detection of DNA lesions via specific signalling (Lagerwerf *et al*, 2011). As DDR is a comprehensive signalling process that determines the cell's ability to repair DNA damage or to undergo apoptosis, its role has been implicated in the disease process and in the successful outcome of chemotherapy (Jasin, 2002; Clingen *et al*, 2008). In line with these findings, aberrant DNA repair pathways appear to have an important role in genomic instability in MM (Velangi *et al*, 2004; Shammas *et al*, 2009). Moreover, Sharma *et al* (2010) have shown that changes in the expression of DNA repair genes may be implicated in the myeloma pathogenesis by leading to genomic instability and accumulation of genetic mutations. Furthermore, Walters *et al* (2011) demonstrated that ongoing DNA damage intensifies across the disease spectrum of normal cells to MM and may be involved in the mechanism whereby clonal evolution occurs in the monoclonal gammopathies. Recently, we have shown that during the malignant transformation in MM, progressive changes in chromatin structure, transcriptional activity and DDR pathways occur in malignant bone marrow plasma cells (BMPCs) and that these changes are also reflected in peripheral blood mononuclear cells (PBMCs; Gkatzamanidou *et al*, 2014). In addition, our previous studies have shown that the efficiency of DNA repair in PBMCs of MM patients could prospectively distinguish between patients with different degrees of therapeutic response, providing the basis for pre-screening and selection of those patients more likely to benefit from this treatment (Souliotis *et al*, 2003; Dimopoulos *et al*, 2005, 2007; Stefanou *et al*, 2012).

There is mounting evidence that the epigenome, as a second dimension of genetic information superimposed onto the DNA helix, is also a key regulator in maintenance of genomic integrity. Significant efforts have shown that epigenetic control mechanisms become deregulated in MM and may be involved in the initiation and progression of the disease, as well as in the outcome of chemotherapy (Chng *et al*, 2007; Fonseca *et al*, 2009). About 15–20% of myeloma tumours are associated with the t(4;14) chromosomal translocation that leads to overexpression of the *MMSET* (MM SET) gene. It has been shown that *MMSET* exhibits

histone methyltransferase activity and its overexpression leads to transcriptional changes of oncogenes and tumour suppressor genes (Chesi and Bergsagel, 2011). Also, Van Haften *et al* (2009) described inactivating somatic mutations in the histone lysine demethylase, UTX, pointing to histone H3 lysine methylation deregulation in multiple tumour types; among them, MM exhibits the highest prevalence (10%). In addition, HDACi have shown significant anti-myeloma activity, highlighting the importance of epigenetic regulation in MM (Smith *et al*, 2010; Hideshima and Anderson, 2013; Richardson *et al*, 2013).

Here, to investigate the mechanism underlying differential response rates to melphalan therapy, we assessed the epigenetic changes and the alteration of DDR signals in malignant BMPCs and PBMCs of newly diagnosed MM patients. We found that changes in chromatin structure and transcriptional activity affect the drug sensitivity of myeloma cells via alteration of the repair efficiency of the TS of active genes and the associated persistence of lesions in this strand, and correlate with the clinical response to melphalan therapy.

## MATERIALS AND METHODS

**Patients.** A total of 110 consecutive, unselected MM patients and healthy controls were included in the present study. Primary cells were collected from 85 ( $n=85$ ) newly diagnosed MM patients (37F/48M; median age 57 years, range 23–71) who were treated in the Department of Clinical Therapeutics at the University of Athens School of Medicine. Twenty-five ( $n=25$ ) healthy individuals, age- and gender-matched patients (11F/14M; median age 55 years, range 26–69), were served as controls.

All patients were staged according to the International Staging System (Greipp *et al*, 2005). All patients received as first-line treatment HDM supported by ASCT. Subsequently, the patients categorised based on their outcome to responders ( $s \geq PR$ ,  $n=57$ ) and non-responders ( $n=28$ ) after melphalan treatment (Table 1). None of the patients had received any anti-myeloma treatment

Table 1. Patient and disease characteristics

Patients			
Characteristics	No.	Years	Total (%)
<b>Sex</b>			
Female	37	—	43.5
Male	48	—	56.5
<b>Age</b>			
Median	—	57	—
Range	—	23–71	—
<b>Response to HDM at day 100</b>			
Complete response	22	—	25.9
Partial response	35	—	41.2
Stable disease	5	—	5.8
Progressive disease	23	—	27.1
<b>Myeloma type</b>			
IgG	56	—	65.9
IgA	16	—	18.8
IgD	5	—	5.9
Light chain only	8	—	9.4

Abbreviations: HDM = high-dose melphalan; Ig = immunoglobulin.

previously, including also any supportive treatment, that is, bisphosphonates. Response assessment was based on the International Myeloma Working Group criteria (Durie *et al*, 2006). The study was approved by the Institutional review board of Alexandra Hospital and all subjects provided informed consent. The study was conducted according to the Declaration of Helsinki.

Peripheral blood was collected from 25 healthy controls and 85 MM patients, and PBMCs were isolated as previously described (Stefanou *et al*, 2012). Bone marrow aspiration samples were obtained from 15 patients during diagnostic clinical assessment. Mononuclear cell suspensions were prepared from bone marrow aspirates by Ficoll-Paque plus gradient centrifugation (Amersham Pharmacia AB, Uppsala, Sweden), and plasma cell isolation from mononuclear cell suspensions was performed by immunomagnetic bead selection with CD138+ using the CD138 MicroBeads and magnet-assisted cell sorting, according to the manufacturer's instructions (Miltenyi Biotec, GmbH, Bergisch Gladbach, Germany). The purity of plasma cells obtained by this method was more than 90% as confirmed by flow cytometry (Becton-Dickinson, San Jose, CA, USA).

**Measurement of transcriptional activity.** Total RNA was extracted from BMPCs and PBMCs using Trizol (Invitrogen, Paisley, UK), slot blotted on Hybond-N+ membrane (Amersham, GE Healthcare Life Sciences, Freiburg, Germany), hybridised to the appropriate <sup>32</sup>P-labelled probe and expression of the genes of interest was evaluated by densitometric analysis (see Supplementary Materials and Methods; Souliotis *et al*, 2006; Episkopou *et al*, 2009).

**Micrococcal nuclease digestion-based analysis.** Isolation of nuclei from BMPCs and PBMCs, digestion with micrococcal nuclease and analysis of chromatin condensation using southern blot were performed as described previously (see Supplementary Materials and Methods; Episkopou *et al*, 2011).

**Measurement of total DNA damage (N-alkylpurines) along the genes.** BMPCs and PBMCs were treated *ex vivo* with 100 µg ml<sup>-1</sup> melphalan for 5 min at 37 °C in RPMI-1640 supplemented with 10% FBS, penicillin (100 U ml<sup>-1</sup>), streptomycin (100 µg ml<sup>-1</sup>) and 2 mmol l<sup>-1</sup> L-glutamine, followed by incubation in drug-free medium for 1 h and DNA damage was analysed thereafter. DNA damage (N-alkylpurines) was measured along the TS and non-TS (NTS) of the N-ras, p53 and d-globin genomic loci using southern blot analysis (see Supplementary Materials and Methods; Episkopou *et al*, 2011). Briefly, genomic DNA was fully digested with BstYI and heated at 70 °C for 30 min for depurination of N-alkylated bases. Subsequently, the apurinic sites were converted to single-strand breaks by adding NaOH for 30 min at 37 °C, size fractionated using agarose gel electrophoresis and southern blotted. Labelling of the oligonucleotides (Supplementary Table 1), hybridizations and calculation of the average frequency of melphalan-induced N-alkylpurine monoadducts in the restriction fragment of interest were performed as described previously (Episkopou *et al*, 2011). In all experiments, an internal standard (part of the N-ras gene) was included.

**Overall genome repair.** BMPCs and PBMCs were exposed to 100 µg ml<sup>-1</sup> melphalan for 5 min, followed by incubation in drug-free medium for 0, 2, 8 and 24 h. Then, the repair of N-alkylpurines in total cellular DNA was determined by a gel electrophoresis method using densitometer scan of photographic negatives of ethidium bromide-stained agarose gels (Souliotis *et al*, 2006).

**Measurement of poly(A) mRNA synthesis.** BMPCs and PBMCs were exposed to 100 µg ml<sup>-1</sup> melphalan for 5 min and the cells were left in drug-free medium for 0–24 h, before pulse labelling with (5,6-<sup>3</sup>H)uridine for 20 min at 37 °C. Then, mRNA was isolated using the MicroPoly(A)Purist Kit (Ambion, Inc., Darmstadt, Germany) isolation system and radioactivity was counted as described previously (Souliotis *et al*, 2006).

**Accumulation of p53 phosphorylated at serine 15.** BMPCs and PBMCs were treated with 0–200 µg ml<sup>-1</sup> melphalan for 5 min and then incubated in drug-free medium for 6 h. Whole-cell protein lysates were subjected to SDS-PAGE and western blotting was conducted as described previously (see Supplementary Materials and Methods; Chauhan *et al*, 2011). The primary antibodies used were anti-p53-phospho-S15 antibody (Abcam, Cambridge, UK; ab38497) and anti-β-actin antibody (loading control; Abcam, ab8227). The lowest concentration of melphalan required to induce detectable levels of p53 phosphorylated at serine 15 (S15P-p53) was noted.

**Apoptotic assay.** BMPCs and PBMCs were treated with various concentrations of melphalan (0–200 µg ml<sup>-1</sup>) for 5 min, followed by incubation in drug-free medium for 24 h. Apoptosis was evaluated using the Cell Death Detection ELISA-PLUS kit (Roche Applied Sciences, Penzberg, Germany), according to manufacturer's instructions (see Supplementary Materials and Methods). This test quantifies apoptosis as a fold increase (expressed as enrichment factor) in the level of apoptosis in treated to untreated samples. The lowest concentration of melphalan required to induce detectable change in the levels of apoptosis (defined as a three-fold increase relative to controls) was noted.


**Statistical analysis.** The efficiency of DNA repair, the accumulation of S15P-p53 and the induction of apoptosis were compared between groups of individuals using nonparametric tests. Specifically, Kruskal–Wallis analysis was used for comparisons across all three groups, and Wilcoxon rank-sum test for the pair-wise comparisons. Correlations between the values of the various DDR-related parameters within BMPC or PBMC of the different MM patients, as well as between the values of BMPC and the corresponding values in PBMC for each DDR-related parameter, were assessed by the Spearman correlation coefficient. For RNA synthesis, data consisted of repeated measurements for each subject at various time points following drug treatment. To account for the within-subject dependency, a clinically meaningful summary variable was created for each subject (Matthews *et al*, 1990). This summary variable was the minimum level that each subject's RNA synthesis reached from time 1 to 24 h. The summary variable was compared across groups using the same nonparametric tests as before. A *P*-value < 0.05 was considered statistically significant. To account for multiple comparisons, the Bonferroni correction was used. Thus, the level of significance for each comparison was set to 0.001. Analysis was performed using STATA statistical software (StataCorp LP, College Station, TX, USA).

## RESULTS

**Chromatin structure, transcriptional activity and DNA repair efficiency affect the drug sensitivity of malignant BMPCs.** We have previously shown a continuous, parallel variation in the transcriptional activity, chromatin condensation and efficiency of TCR by using human primary fibroblasts (Episkopou *et al*, 2009). Here, these three biological end points were analysed in malignant BMPCs from 15 newly diagnosed MM patients who went on to receive melphalan as first-line treatment (9 responders and 6 non-responders).

Measurement of the steady-state RNA levels in BMPCs using slot-blot analysis revealed that the N-ras and p53 genes were active in all patients, whereas d-globin gene was expressed in 11 out of 15 patients (7 out of 9 responders and 4 out of 6 non-responders). Significant differences in the expression levels of these genes were observed between the above-mentioned groups (all *P* < 0.001), with the transcriptional activity of all three genes being higher in non-responders in comparison with responders (Figure 1A and D; Table 2).

We also analysed chromatin condensation in different regions of the three genes examined (Figure 1C). Using MN digestion,



**Figure 1.** Transcriptional activity and chromatin condensation in untreated primary cells. Representative autoradiograms showing RNA slot blots (**A**) in malignant BMPCs and (**B**) in PBMCs from one healthy volunteer (HV), one MM patient responder (R) and one non-responder (NR) to melphalan therapy.  $\beta$ -Actin was used as normalisation/loading control. (**C**) The gene loci where chromatin condensation and region-specific repair were evaluated. Black boxes, transcribed regions of the genes. (**D**) Box plots showing statistical distribution of the steady-state RNA levels in non-responders as a ratio to that of responders in the *N-ras*, *p53* and *d-globin* genes, in the untreated PBMCs and BMPCs. The horizontal lines within the boxes represent the median value and the vertical lines extending above and below the boxes indicate maximum and minimum values, respectively. Representative autoradiograms showing chromatin condensation in the malignant BMPCs along the active *N-ras* (**E**) and *p53* (**F**) genes in all subjects, the active *d-globin* gene in 11 out of 15 MM patients (**G**) and the silent *d-globin* gene in 4 out of 15 MM patients (**H**). Moreover, representative autoradiograms showing chromatin condensation in the malignant BMPCs from MM patients responders and non-responders in the FN4 fragment of the active *N-ras* (**I**), in the FP7 of the active *p53* (**J**), in the FD3 of the active *d-globin* (**K**) and in the FD3 fragment of the silent *d-globin* genes (**L**). Symbols M, D, Tri and Tet represent the positions of nucleosome monomer, dimer, trimer and tetramer, respectively.

a gradient of the local chromatin structure was found along the transcribed genes, with greater looseness of chromatin structure in regions near the transcription start site (Figure 1E and F). Chromatin looseness becomes lowest outside the transcribed regions (Figure 1E and G). That is, FN3 fragment (located at the 5'-end of the active *N-ras* gene) is in mono- and dinucleosome structures, with a significant portion in mononucleosomes (Figure 1E), FN5 fragment (at the 3'-end of the same gene) is in mono-, di-, tri- and tetranucleosomes, whereas FN1 fragment (located outside the *N-ras* gene) is in di-, tri-, tetranucleosomes and higher structures. Similar results were obtained using the other active genes (Figure 1F and G). Notably, the silent *d-globin* gene was in di-, tri-, tetranucleosomes and higher structures in all three regions analysed, located either outside (FD1, FD4) or inside (FD3) the gene (Figure 1H).

As regards, DNA repair, our previous studies suggest that the repair efficiency of *N*-alkylpurine monoadducts (precursors of cytotoxic ICL) has an important role in protecting cells from melphalan cytotoxicity and may be a significant factor leading to chemotherapy failure (Souliotis *et al*, 2006; Episkopou *et al*, 2009; Stefanou *et al*, 2012). Therefore, in the present study, DNA damage was measured within 1 h of *ex vivo* melphalan treatment, a time point at which DNA damage consists almost exclusively from monoadducts (Souliotis *et al*, 2006). In agreement with the chromatin condensation results, a gradient of the DNA repair

efficiency was found at different regions along the active genes, with higher repair efficiency in regions close to the transcription start site (Figure 2). DNA repair efficiency becomes lowest outside the transcribed regions. In the four patients (two responders and two non-responders) with inactive *d-globin* gene, the levels of repair efficiency were similar at the different DNA regions of this gene (Figure 2H and I).

Interestingly, significant differences between responders and non-responders, in both local chromatin structure and DNA repair efficiency, were observed at specific genomic sites. That is, at regions located inside the active genes, the looseness of the local chromatin structure (Figure 1I–K) and the DNA repair efficiency in the TS of active genes (Figure 2A, B, D and F) were significantly higher in non-responders than in responders (all  $P < 0.04$ ; Table 2). In contrast, no difference in the repair efficiency between responders and non-responders was observed (a) in the fragments located outside the active genes (FN1 in all patients; FD1 and FD4 in 11 patients with transcribed *d-globin* gene; Table 2; Figure 2B and F) and (b) in the NTS of all three genes examined in all patients (Figure 2C, E, G and I). Moreover, in the four patients with inactive *d-globin* gene, no difference was found between responders ( $n = 2$ ) and non-responders ( $n = 2$ ) in both the local chromatin condensation (Figure 1L) and the repair efficiency of the TS (Figure 2H). Finally, no difference was found among groups of individuals in the overall genome repair efficiency of melphalan

Table 2. DNA damage response-related parameters and associated Wilcoxon rank-sum tests in BMPCs

DDR parameters	Fragment name	Mean (range)		Wilcoxon rank-sum tests (P-values)
		Responders (n = 9)	Non-responders (n = 6)	Responders vs non-responders
Transcription N-ras <sup>a</sup>	—	16.1 (10.2–22.6)	45.7 (37.1–56.9)	<0.001
Transcription p53 <sup>a</sup>	—	71.7 (7.3–93.2)	109.7 (83.4–147.6)	<0.001
Transcription d-globin <sup>a</sup>	—	16.4 (0–34)	38.0 (0–97.3)	<0.001
Chromatin N-ras <sup>b</sup>	—	14.4 (8.4–20.7)	34.2 (25.6–41.7)	<0.001
Chromatin p53 <sup>b</sup>	—	54.4 (42.1–65.8)	81.2 (70.3–91.4)	0.02
Chromatin d-globin <sup>b</sup>	—	13.9 (5.0–22.4)	62.5 (55.9–70.1)	<0.001
Active N-Ras gene <sup>c</sup>	FN1	158.7 (136–185)	155.7 (140–170)	0.527
	FN2	138.3 (120–155)	109.0 (95–135)	0.002
	FN3	54.1 (43–65)	24.7 (15–33)	0.001
	FN4	97.1 (80–113)	40.3 (20–54)	<0.0001
	FN5	117.9 (102–134)	103.0 (90–115)	0.04
Active p53 gene <sup>c</sup>	FP5	8.3 (3–14)	2.0 (0–4)	0.05
	FP6	17.8 (15–22)	2.3 (0–5)	0.001
	FP7	66.1 (50–80)	35.3 (25–45)	<0.0001
	FP8	84.0 (68–103)	60.2 (48–72)	<0.0001
Active d-globin gene <sup>c,d</sup>	FD1	152.8 (139–167)	149.8 (129–170)	0.597
	FD2	134 (115–155)	92.2 (80–105)	0.001
	FD3	126.2 (112–139)	2.5 (0–10)	<0.0001
	FD4	141.2 (124–162)	138 (122–158)	0.698
RNA synthesis <sup>e</sup>	—	25 (15–40)	55 (45–75)	<0.0001
S15P-p53 accumulation <sup>f</sup>	—	45.2 (30–60)	70.8 (55–90)	0.001
Apoptosis <sup>g</sup>	—	33.9 (15–50)	61.7 (45–80)	<0.0001


Abbreviations: BMPCs = bone marrow plasma cells; DDR = DNA damage response.  
<sup>a</sup>Steady-state RNA levels (as the ratio to that of the  $\beta$ -actin).  
<sup>b</sup>Chromatin condensation (as % of mononucleosomes following micrococcal nuclease digestion).  
<sup>c</sup>DNA damage in the transcribed strand (adducts per  $10^6$  nucleotides).  
<sup>d</sup>Activation of d-globin was found in 7 out of 9 responders and 4 out of 6 non-responders.  
<sup>e</sup>The lowest levels of RNA synthesis (% control).  
<sup>f</sup>The lowest concentration of melphalan required to induce detectable levels of S15P-p53 ( $\mu\text{g ml}^{-1}$ ).  
<sup>g</sup>The lowest concentration of melphalan required to induce detectable change in the levels of apoptosis ( $\mu\text{g ml}^{-1}$ ).

N-alkylpurines, indicating that the active global repair processes in the removal of N-alkylpurines were not significantly affected in MM patients (Figure 2J and K).


The above observations indicate that malignant BMPCs from non-responders to melphalan therapy are characterised by greater looseness of chromatin structure in transcribed genes compared with responders that results in higher repair efficiency of melphalan-induced DNA damage in the TS, which in turn affects drug sensitivity of these cells and is involved in the resistance to melphalan therapy. Thus, we hypothesised that accumulation of DNA damage in the TS, as a result of its reduced repair efficiency, leads to blocked transcription and activation of the apoptotic pathway. To test this hypothesis, we first measured the inhibition and recovery of mRNA synthesis following treatment of BMPCs with melphalan. In both groups of patients, the lowest levels of mRNA synthesis were observed 1 h following melphalan treatment (Figure 3A). Interestingly, the severity of the inhibition of mRNA synthesis was higher in responders than in non-responders and correlated inversely with the repair efficiency of the TS of active genes (all  $P < 0.0001$ , Table 2). In addition, non-responders fully recovered mRNA synthesis to control levels by 6 h following treatment, whereas responders recovered mRNA synthesis only at 24 h following treatment (Figure 3A). These results suggest that the

fast removal of transcription blocking lesions is crucial for the cell to escape from the lethal effects of inhibited transcription. That is, BMPCs from non-responders repair melphalan-induced N-alkylpurines located in the TS very rapidly resulting in fewer remaining DNA lesions, low number of blocked RNA polymerase II molecules and thus lower severity and faster recovery of transcription inhibition. In contrast, the higher severity and prolonged duration of blockage of RNA polymerase machinery observed in BMPCs from responders is attributed to inferior DNA repair efficiency of the TS and consequently high number of unrepaired DNA N-alkylpurines that could block RNA polymerase and consequently lead to apoptosis.

It is well known that the tumour suppressor p53 is a critical mediator of cellular responses to genotoxic stress. Following DNA damage, post-translational modification involving phosphorylation of p53 on serine 15 is causally associated with induction of apoptosis via the increased expression of specific p53-responsive pro-apoptotic genes (Amano *et al*, 2009). Therefore, BMPCs were treated with melphalan and the accumulation of the serine 15-phosphorylated form of the p53 protein was measured. In accordance with the results on the inhibition of mRNA synthesis, we found that the concentrations of melphalan required for the induction of S15P-p53 were higher in non-responders than in



**Figure 2.** Region-specific repair of melphalan-induced damage along the *N-ras*, *p53* and *d-globin* genes in BMPCs. **(A)** Representative autoradiograms showing southern blot analysis of melphalan-dependent loss of signal from the full-length (non-treated) band as a result of *N*-alkylpurine formation in the TS and NTS of the FN4 fragment of the *N-ras* gene from one MM patient responder (R) and one non-responder (NR) to melphalan therapy. Box plots showing statistical distribution of melphalan-induced *N*-alkylpurine levels in responders and non-responders to melphalan therapy, in different regions of the TS (**A**, **B**, **D**, **F**, **H**) and the NTS (**A**, **C**, **E**, **G**, **I**) of the active *N-ras* (**A**–**C**) and *p53* genes (**D**, **E**) in all patients, the active *d-globin* gene in 11 out of 15 MM patients (**F**, **G**) and the silent *d-globin* gene in 4 out of 15 MM patients (**H**, **I**). The horizontal lines within the boxes represent the median value and the vertical lines extending above and below the boxes indicate maximum and minimum values, respectively. **(J)** Overall genome repair at various time points (0–24 h) following melphalan treatment of BMPC from one patient responder and non-responder to melphalan therapy. DNAs were electrophoresed in a 0.6% agarose gel and stained with ethidium bromide. Kb = kilobases; U = untreated samples. **(K)** Presented are data derived from densitometric analysis of the overall genome repair. The data are based on two biological experiments and several gels from each. The error bars represent s.d. Abbreviation: nucl = nucleotides.



**Figure 3.** The induction of the apoptotic pathway in BMPCs and PBMCs following melphalan treatment. Vertical bar charts show mRNA synthesis in malignant BMPCs (A) and in PBMCs (B). R = responders; NR = non-responders; H = healthy controls. (C) Western blots show the accumulation of S15P-p53 from one healthy volunteer (HV), one MM patient responder and one MM patient non-responder, in PBMCs representative of both tissues analysed.  $\beta$ -Actin was used as normalisation/loading control. Box plots showing the statistical distribution of the lowest concentration of melphalan required to induce (D) detectable levels of S15P-p53 and (F) detectable change in the levels of apoptosis (defined as a three-fold increase relative to controls) are presented. The horizontal lines within the boxes represent the median value and the vertical lines extending above and below the box indicate maximum and minimum values, respectively. (E) The correlation between the lowest concentration of melphalan required to induce detectable levels of S15P-p53 in malignant BMPCs and in PBMCs from the same patients. (G) The correlation between the lowest concentration of melphalan required to induce detectable change in the levels of apoptosis in malignant BMPCs and in PBMCs from the same patients. Finally, the correlation between the lowest melphalan concentrations inducing phosphorylation of p53 at serine 15 and those inducing apoptosis in malignant BMPCs (H) and in PBMCs (I) are presented. The lines represent the theoretical line for a perfect correlation between the two sets of data.

responders (all  $P=0.001$ ; Table 2; Figure 3D), indicating that the ability of BMPCs to phosphorylate p53 on serine 15 was inversely correlated with the repair efficiency of the TS. Specifically, BMPCs from responders showed evidence of p53 phosphorylation at melphalan concentrations as low as  $45.2 \pm 11.7 \mu\text{g ml}^{-1}$ , whereas non-responders required concentrations of  $70.8 \pm 13.2 \mu\text{g ml}^{-1}$  (Table 2).

Also, BMPCs were *ex vivo* treated with various concentrations of melphalan and the induction of apoptosis was measured 24 h after the end of the treatment using the Cell Death Detection ELISA-PLUS kit. In agreement with the above results and in harmony with our hypothesis, we found that the lowest concentrations of melphalan required for the induction of apoptosis were higher in non-responders compared with responders (all  $P<0.0001$ ; Table 2; Figure 3F), indicating that the

induction of apoptosis was inversely correlated with the repair efficiency of the TS. A melphalan concentration as low as  $33.9 \pm 12.2 \mu\text{g ml}^{-1}$  was sufficient to induce detectable levels of apoptosis in responders, whereas non-responders required concentrations of  $61.7 \pm 14.0 \mu\text{g ml}^{-1}$ .

**Molecular differences between responders and non-responders are reflected in PBMCs.** To use blood leukocyte molecular parameters as biomarkers for prediction of clinical response, their relationship with the respective parameters of the target cells must be ensured. Thus, transcription activity, chromatin structure and DDR signals were evaluated at the same model loci (N-ras, p53, d-globin) in PBMCs from 25 healthy controls and 85 MM patients (including the 15 patients mentioned above—paired samples), 57 responders and 28 non-responders to melphalan therapy.



In agreement with the results of BMPC experiments, measurement of the steady-state RNA levels in PBMCs showed that the *N-ras* and *p53* genes were active in all subjects, whereas the *d-globin* gene was silent in all healthy controls and transcribed in 68 out of 85 MM patients (46 out of 57 responders and 22 out of 28 non-responders; Episkopou *et al*, 2009; Gkotzamanidou *et al*, 2014). Significant differences were observed among the groups of individuals in the expression levels of the genes (all  $P < 0.01$ ), with the transcriptional activity of all genes being significantly higher in non-responders than in responders and lowest in healthy volunteers (Figure 1B and D; Supplementary Table 2).

Similarly, in all subjects, we found that the local chromatin condensation (data not shown) and the DNA repair efficiency following *ex vivo* treatment with melphalan show a strong gradient, decreasing from the 5'- to the 3'-end of the transcribed regions of the expressed genes (Figure 4A, B, D and E; Supplementary Figure 1A and B). Chromatin looseness and DNA repair efficiency become lowest in regions located inside the silent *d-globin* gene and outside all genes examined.

More interestingly, significant differences in the chromatin structure and the repair efficiency of the TS of active genes were observed among the three groups of individuals. Specifically, at regions located inside the genes, the looseness of the local chromatin structure and the DNA repair efficiency of the TS (Figure 4A and D; Supplementary Figure 1A) were higher in non-responders than in responders and lowest in healthy controls (all  $P < 0.05$ ; Supplementary Table 2). On the contrary, no difference in the repair efficiency between responders and non-responders was observed (a) in the fragments located outside the active genes (FN1 of the *N-ras* in all patients; FD1 and FD4 in 68 patients with active *d-globin* gene; Supplementary Table 2; Figure 4A; Supplementary

Figure 1A), (b) in the FP5 and FP6 of the *p53* gene where repair activity was extremely high in all individuals (Supplementary Table 2; Figure 4D), (c) in the silent *d-globin* gene (11 responders and 6 non-responders; Supplementary Figure 1C and D), (d) in the NTS of all three genes examined (Figure 4B and E; Supplementary Figure 1B and D) and (e) in the overall genome (data not shown). Remarkably, significant correlations between PBMCs and BMPCs from the same patients ( $n = 15$ ) were observed in the repair efficiency of all genes examined (*N-ras*, linear regression models  $r^2 = 0.831$ ,  $P < 0.001$ ; *p53*,  $r^2 = 0.751$ ,  $P < 0.001$ ; *d-globin*,  $r^2 = 0.573$ ,  $P = 0.01$ ; Figure 4C and F; Supplementary Figure 1E).

Consistent with BMPC findings, significant differences among groups of individuals were observed in the ability of PBMCs to induce the apoptotic pathway. The severity and the duration of the inhibition of the RNA synthesis (all  $P < 0.0001$ ; Supplementary Table 2; Figure 3B), the accumulation of S15P-p53 (all  $P < 0.0001$ ; Supplementary Table 2; Figure 3C and D) and the induction of apoptosis (all  $P < 0.0001$ ; Supplementary Table 2; Figure 3F) in PBMCs correlated inversely with the repair efficiency of the TS of active genes and varied in the order healthy controls > responders > non-responders. More importantly, significant correlations were found between PBMCs and BMPCs from the same patients ( $n = 15$ ) in the phosphorylation of p53 on serine 15 (linear regression models  $r^2 = 0.48$ ,  $P < 0.01$ ) and the induction of apoptosis (linear regression models  $r^2 = 0.62$ ,  $P < 0.001$ ) as shown in Figure 3E and G, respectively. Finally, the observed range of changes in all examined end points in PBMCs from MM patients was not present in PBMCs among healthy controls, supporting the disease-associated nature of the defects in DDR pathways and chromatin structure reflected in cells of the peripheral blood of MM patients.




Figure 4. Region-specific repair of melphalan-induced damage along the active *N-ras* and *p53* genes in PBMCs. Box plots are showing the statistical distribution of melphalan-induced *N*-alkylpurine levels in healthy volunteers (HV) and MM patients, responders (R) and non-responders (NR), in different regions of the TS (A, D) and the NTS (B, E) of the *N-ras* (A, B) and *p53* (D, E) genes. The horizontal lines within the boxes represent the median value and the vertical lines extending above and below the boxes indicate maximum and minimum values, respectively. Correlation between DNA damage in malignant BMPCs and DNA damage in PBMCs from the same patients in the *N-ras* (C) and *p53* (F) genes. Abbreviations: melph = melphalan; nucl = nucleotides.

DISCUSSION

The apoptotic elimination of cells having sustained DNA damage is a critical mechanism in tumour suppression (Cho and Liang, 2011). In our study, we observed differential induction of apoptosis by the DNA-damaging agent melphalan in BMPCs of MM patients, who differ in their ability to process the corresponding DNA damage, and we demonstrate that such induction correlates with the repair efficiency of the TS of active genes and the patient therapeutic response. Interestingly, these molecular parameters were reflected in PBMCs of the same MM patients.

Significant differences between the groups of patients were observed in the local chromatin condensation, the state of transcription and the repair efficiency of melphalan-induced *N*-alkylpurines in the TS of active genes. Particularly, the looseness of the local chromatin structure and the expression levels at selected model loci (inside the active *N-ras*, *p53* and *d-globin* genes) were higher in non-responders than in responders to melphalan therapy. Also, in line with our previously published data where the repair efficiency in different gene loci correlated with the local chromatin condensation and the transcriptional activity (Episkopou *et al*, 2009), we found significant differences (all  $P < 0.04$ ; Table 2; Supplementary Table 2) between the two groups of patients in the repair efficiency of the TS of active genes

(repaired by the TCR subpathway of NER), with the efficiency being higher in non-responders than in responders. No such differences were found in the repair efficiency of the NTS (repaired by the GGR subpathway of NER) or in the overall genome repair, suggesting that the key determinant of the cytotoxicity of melphalan and the chemotherapy outcome is the efficiency of TCR and the associated persistence of lesions in the TS of active genes.

In agreement with the above suggestion, following *ex vivo* treatment of both BMPCs and PBMCs with melphalan, we observed significant differences among the groups of patients in the induction of the apoptotic pathway (all  $P < 0.001$ ; Table 2; Supplementary Table 2). In particular, we found that the severity and duration of the inhibition of mRNA synthesis, the phosphorylation of the p53 at serine 15 and the induction of apoptosis inversely correlated with the repair efficiency of the TS, and were all higher in responders than in non-responders. On the contrary, no such correlation was detected for the repair efficiency of the NTS. These data are in accordance with our previous observations in human fibroblasts showing that cells with low repair efficiency of the TS (GGR+/TCR-) exhibited stronger inhibition and slower recovery of mRNA synthesis than those with low repair efficiency of the NTS (GGR-/TCR+), as well as that loss of TCR (GGR+/TCR-) had a greater effect on resistance than did loss of GGR (GGR-/TCR+; Episkopou *et al*, 2009). Similarly, Enou




Figure 5. The mechanistic basis for the link between DNA repair efficiency and the response to melphalan therapy. Reduced repair efficiency of the TS of active genes correlates with high numbers of blocked RNA polymerase II complexes acting as lesion detectors, phosphorylation of p53 at serine 15, increased cellular chemosensitivity and better clinical response to melphalan therapy.

*et al* (2012) have showed that transcription-dependent pathways contribute to cellular survival following crosslinking-agents' treatment. In addition, the suppression of the apoptotic pathway observed in PBMCs of MM patients compared with healthy controls enhances previous studies that have shown that apoptosis and senescence in precancerous cells are barriers to tumorigenesis, whereas both of these cellular responses are suppressed during cancer progression (Gorgoulis *et al*, 2005; Bartkova *et al*, 2006; Halazonetis *et al*, 2008). The strong correlation observed between the accumulation of S15P-p53 and apoptosis (BMPC, linear regression models  $r^2 = 0.98$ ,  $P < 0.001$ ; PBMC,  $r^2 = 0.39$ ,  $P = 0.05$ ; Figure 3H and I) in both BMPCs and PBMCs of MM patients is compatible with previous reports, which showed that blockage of the RNA polymerase II complex at DNA lesions elicits a signal that triggers the induction of p53 and the execution of the apoptotic programme (Ljungman *et al*, 1999), and supports a direct role for p53 in the activation of melphalan-induced apoptosis. Although the evidence presented in this study emphasises the importance of DDR, especially TCR, in determining the therapeutic impact of melphalan treatment at the individual level, it is likely that additional mechanisms (that is, repair of DNA lesions downstream of melphalan-DNA *N*-alkylpurines, such as ICL and double-strand breaks (Gourzones-Dmitriev *et al*, 2013), defects in drug transport systems resulting in reduced drug uptake (Tew, 1994) and increased binding to glutathione (Moscow *et al*, 1993)) modify therapeutic response and may also constitute useful tools for the identification of melphalan-sensitive MM patients.

Examination of the ranking of the different subjects in relation to each of the DDR-related parameters analysed shows a high degree of correlation for all pair-wise comparisons, in both BMPC and PBMC, with the Spearman correlation coefficients ranging 0.83–0.97 if d-globin transcription (which shows a significant but lower correlation) is excluded (Supplementary Tables 3 and 4). A similar correlation is seen when subject ranking in relation to each DDR-related parameter is compared between the two tissues (Supplementary Table 5). These observations suggest the existence of consistent phenotypic trait related to DDR, which determines individual response to therapeutic treatment and whose characterisation in PBMC can be used to predict its state in BMPC.

Taken together, our findings suggest a mechanistic basis for the link between DNA repair efficiency and the response to melphalan therapy. More specifically, in accordance with our previous study (Gkatzamanidou *et al*, 2014), we found significant differences among MM patients in the degree of chromatin condensation and transcription activity of the malignant BMPCs. As the condensation status is known to affect DNA repair, MM patients with more condensed chromatin structure in active genes show lower repair efficiency of melphalan-induced DNA damage in the TS and prolonged inhibition of RNA polymerase II-driven transcription, which in turn triggers the induction of the p53-dependent apoptotic pathway, a priority for successful clinical outcome; these patients exhibit better clinical response to melphalan treatment (Figure 5). Moreover, as the molecular changes between responders and non-responders observed in cancer BMPCs are also reflected in a readily accessible tissue (PBMCs), these data might eventually be translated into novel indicators for selection of MM patients who are more likely to benefit from subsequent melphalan therapy.

## ACKNOWLEDGEMENTS

We would like to thank Professor Kenneth C Anderson (Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA) and Dr Evangelos Terpos (Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece) for their helpful comments

and suggestions. This work was partly supported by the ECNIS (Environmental Cancer, Nutrition and Individual Susceptibility) Network of Excellence of the European Union (contract no. 513943).

## CONFLICT OF INTEREST

The authors declare no conflict of interest.

## AUTHOR CONTRIBUTIONS

MG performed the epigenetic and DNA damage response experiments, collected and analysed the data and wrote the manuscript; PPS and SAK evaluated results and reviewed the manuscript; CB performed the statistical analysis of data and reviewed the manuscript; MAD was responsible for the selection and clinical evaluation of patients and reviewed the manuscript; and VLS designed and supervised the research, performed the epigenetic and DNA damage response experiments, analysed data and wrote the manuscript. All the authors reviewed and approved the final version of this manuscript.

## REFERENCES

- Amano T, Nakamizo A, Mishra SK, Gumin J, Shinojima N, Sawaya R, Lang FF (2009) Simultaneous phosphorylation of p53 at serine 15 and 20 induces apoptosis in human glioma cells by increasing expression of pro-apoptotic genes. *J Neurooncol* **92**: 357–371.
- Anderson KC (2012) The 39th David A. Karnofsky Lecture: bench-to bedside translation of targeted therapies in multiple myeloma. *J Clin Oncol* **30**: 445–452.
- Balcome S, Park S, Quirk Dorr DR, Hafner L, Phillips L (2004) Adenine-containing DNA-DNA cross-links of antitumor nitrogen mustards. *Chem Res Toxicol* **17**: 950–962.
- Barlogie B, Hall R, Zander A, Dicke K, Alexanian R (1986) High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. *Blood* **67**: 1298–1301.
- Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N, Vassiliou LV, Koletta E, Niforou K, Zoumpourlis VC, Takaoka M, Nakagawa H, Tort F, Fugger K, Johansson F, Sehested M, Andersen CL, Dyrskjot L, Ørntoft T, Lukas J, Kittas C, Helleday T, Halazonetis TD, Bartek J, Gorgoulis VG (2006) Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. *Nature* **444**: 633–637.
- Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orłowski R, Bladé J, Sezer O, Ludwig H, Dimopoulos MA, Attal M, Sonneveld P, Boccadoro M, Anderson KC, Richardson PG, Bensinger W, Johnsen HE, Kroeger N, Gahrton G, Bergsagel PL, Vesole DH, Einsele H, Jagannath S, Niesvizky R, Durie BG, San Miguel J, Lonial S. International Myeloma Working Group (2011) International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. *Blood* **117**: 6063–6073.
- Chauhan D, Tian Z, Zhou B, Kuhn D, Orłowski R, Raje N, Richardson P, Anderson KC (2011) *In vitro* and *in vivo* selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. *Clin Cancer Res* **17**: 5311–5321.
- Chesi M, Bergsagel PL (2011) Many multiple myelomas: making more of the molecular mayhem. *Hematology Am Soc Hematol Educ Program* **2011**: 344–353.
- Chng WJ, Glebov O, Bergsagel PL, Kuehl WM (2007) Genetic events in the pathogenesis of multiple myeloma. *Best Pract Res Clin Haematol* **20**: 571–596.
- Cho YJ, Liang P (2011) S-phase-coupled apoptosis in tumor suppression. *Cell Mol Life Sci* **68**: 1883–1896.
- Clingen PH, Wu JY, Miller J, Mistry N, Chin F, Wynne P, Prise KM, Hartley JA (2008) Histone H2AX phosphorylation as a molecular pharmacological marker for DNA interstrand crosslink cancer chemotherapy. *Biochem Pharmacol* **76**: 19–27.
- Deans AJ, West SC (2011) DNA interstrand crosslink repair and cancer. *Nat Rev Cancer* **11**: 467–480.

- Dimopoulos MA, Souliotis VL, Anagnostopoulos A, Bamia C, Pouli A, Baltadakis I, Terpos E, Kyrtopoulos SA, Sfikakis PP (2007) Melphalan-induced DNA damage *in vitro* as a predictor for clinical outcome in multiple myeloma. *Haematologica* **92**: 1505–1512.
- Dimopoulos MA, Souliotis VL, Anagnostopoulos A, Papadimitriou C, Sfikakis PP (2005) Extent of damage and repair in the p53 tumor-suppressor gene after treatment of myeloma patients with high-dose melphalan and autologous blood stem-cell transplantation is individualized and may predict clinical outcome. *J Clin Oncol* **23**: 4381–4389.
- Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadoro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV. International Myeloma Working Group (2006) International uniform response criteria for multiple myeloma. *Leukemia* **20**: 1467–1473.
- Eidler M, Jakubowski N, Linscheid M (2006) Quantitative determination of melphalan DNA adducts using HPLC inductively coupled mass spectrometry. *J Mass Spectrom* **41**: 507–516.
- Enoiu M, Jiricny J, Schärer OD (2012) Repair of cisplatin-induced DNA interstrand crosslinks by a replication-independent pathway involving transcription-coupled repair and translesion synthesis. *Nucleic Acids Res* **40**: 8953–8964.
- Episkopou H, Kyrtopoulos SA, Sfikakis PP, Dimopoulos MA, Souliotis VL (2011) The repair of melphalan-induced DNA adducts in the transcribed strand of active genes is subject to a strong polarity effect. *Mutat Res* **714**: 78–87.
- Episkopou H, Kyrtopoulos SA, Sfikakis PP, Fousteri M, Dimopoulos MA, Mullenders LHF, Souliotis VL (2009) Association between transcriptional activity, local chromatin structure and the efficiencies of both subpathways of nucleotide excision repair of melphalan adducts. *Cancer Res* **69**: 4424–4433.
- Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, Morgan G, Van Ness B, Chesi M, Minvielle S, Neri A, Barlogie B, Kuehl WM, Liebisch P, Davies F, Chen-Kiang S, Durie BG, Carrasco R, Sezer O, Reiman T, Pilarski L, Avet-Loiseau H. International Myeloma Working Group (2009) International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. *Leukemia* **23**: 2210–2221.
- Giral S (2010) 200 mg/m<sup>2</sup> melphalan—the gold standard for multiple myeloma. *Nat Rev Clin Oncol* **7**: 490–491.
- Gkatzamanidou M, Terpos E, Bamia C, Kyrtopoulos SA, Sfikakis PP, Dimopoulos MA, Souliotis VL (2014) Progressive changes in chromatin structure and DNA damage response signals in bone marrow and peripheral blood during myelomagenesis. *Leukemia* **28**: 1113–1121.
- Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, Ditullio Jr RA, Kastrinakis NG, Levy B, Kleitman S, Yoneta A, Herlyn M, Kittas C, Halazonetis TD (2005) Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. *Nature* **434**: 907–913.
- Gourzones-Dmitriev C, Kassambara A, Sahota S, Rème T, Moreaux J, Bourquard P, Hose D, Pasero P, Constantinou A, Klein B (2013) DNA repair pathways in human multiple myeloma: role in oncogenesis and potential targets for treatment. *Cell Cycle* **12**: 2760–2773.
- Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J (2005) International staging system for multiple myeloma. *J Clin Oncol* **23**: 3412–3420.
- Halazonetis TD, Gorgoulis VG, Bartek J (2008) An oncogene-induced DNA damage model for cancer development. *Science* **319**: 1352–1355.
- Hendriks G, Jansen JG, Mullenders LH, de Wind N (2010) Transcription-coupled repair and apoptosis provide specific protection against transcription-associated mutagenesis by ultraviolet light. *Transcription* **1**: 95–98.
- Hideshima T, Anderson KC (2013) Histone deacetylase inhibitors in the treatment for multiple myeloma. *Int J Hematol* **97**: 324–332.
- Jasin M (2002) Homologous repair of DNA damage and tumorigenesis: the BRCA connection. *Oncogene* **21**: 8981–8993.
- Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, LeLeu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Bladé J, Goldschmidt H, Jagannath S, Miguel JS, Orłowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG. International Myeloma Working Group (2012) Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter International Myeloma Working Group study. *Leukemia* **26**: 149–157.
- Lagerwerf S, Vrouwe MG, Overmeer RM, Fousteri MI, Mullenders LH (2011) DNA damage response and transcription. *DNA Repair (Amst)* **10**: 743–750.
- Ljungman M, Zhang F, Chen F, Rainbow AJ, McKay BC (1999) Inhibition of RNA polymerase II as a trigger for the p53 response. *Oncogene* **18**: 583–592.
- Matthews JN, Altman DG, Campbell MJ, Royston P (1990) Analysis of serial measurements in medical research. *BMJ* **300**: 230–235.
- Moscow JA, Swanson CA, Cowan KH (1993) Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan. *Br J Cancer* **68**: 732–737.
- Palumbo A, Anderson K (2011) Multiple myeloma. *N Engl J Med* **364**: 1046–1060.
- Redic K (2013) Carfilzomib: a novel agent for multiple myeloma. *J Pharm Pharmacol* **65**: 1095–1106.
- Richardson PG, Mitsiades CS, Laubach JP, Hajeck R, Spicka I, Dimopoulos MA, Moreau P, Siegel DS, Jagannath S, Anderson KC (2013) Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. *Leuk Res* **37**: 829–837.
- San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG. VISTA Trial Investigators (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. *N Engl J Med* **359**: 906–917.
- Shammas MA, Shmookler Reis RJ, Koley H, Batchu RB, Li C, Munshi NC (2009) Dysfunctional homologous recombination mediates genomic instability and progression in myeloma. *Blood* **113**: 2290–2297.
- Sharma A, Heuck CJ, Fazzari MJ, Mehta J, Singhal S, Grealley JM, Verma A (2010) DNA methylation alterations in multiple myeloma as a model for epigenetic changes in cancer. *Wiley Interdiscip Rev Syst Biol Med* **2**: 654–669.
- Smith EM, Boyd K, Davies FE (2010) The potential role of epigenetic therapy in multiple myeloma. *Br J Haematol* **148**: 702–713.
- Souliotis VL, Dimopoulos MA, Episkopou HG, Kyrtopoulos SA, Sfikakis PP (2006) Preferential *in vivo* DNA repair of melphalan-induced damage in human genes is greatly affected by the local chromatin structure. *DNA Repair (Amst)* **5**: 972–985.
- Souliotis VL, Dimopoulos MA, Sfikakis PP (2003) Gene-specific formation and repair of DNA monoadducts and interstrand cross-links after therapeutic exposure to nitrogen mustards. *Clin Cancer Res* **9**: 4465–4474.
- Spanwick VJ, Craddock C, Sekhar M, Mahendra P, Shankaranarayana P, Hughes RG, Hochhauser D, Hartley JA (2002) Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. *Blood* **100**: 224–229.
- Stefanou DT, Episkopou H, Kyrtopoulos SA, Bamias A, Gkatzamanidou M, Bamia C, Liakou C, Bekyrou M, Sfikakis PP, Dimopoulos MA, Souliotis VL (2012) Development and validation of a PCR-based assay for the selection of patients more likely to benefit from therapeutic treatment with alkylating agents. *Br J Clin Pharmacol* **74**: 842–853.
- Tew KD (1994) Glutathione-associated enzymes in anticancer drug resistance. *Cancer Res* **54**: 4313–4320.
- Thompson LH, Hinz JM (2009) Cellular and molecular consequences of defective Fanconi anemia proteins in replication-coupled DNA repair: mechanistic insights. *Mutat Res* **668**: 54–72.
- Van Haften G, Dalglish GL, Davies H, Chen L, Bignell G, Greenman C, Edkins S, Hardy C, O'Meara S, Teague J, Butler A, Hinton J, Latimer C, Andrews J, Barthorpe S, Beare D, Buck G, Campbell PJ, Cole J, Forbes S, Jia M, Jones D, Kok CY, Leroy C, Lin ML, McBride DJ, Maddison M, Maquire S, McLay K, Menzies A, Mironenko T, Mulderrig L, Mudie L, Pleasance E, Shepherd R, Smith R, Stebbings L, Stephens P, Tang G, Tarpey PS, Turner R, Turrell K, Varian J, West S, Widaa S, Wray P, Collins VP, Ichimura K, Law S, Wong J, Yuen ST, Leung SY, Tonon G, DePinho RA, Tai YT, Anderson KC, Kahnoski RJ, Massie A, Khoo SK, Teh BT, Stratton MR, Futreal PA (2009) Somatic mutations of

the histone H3K27 demethylase gene UTX in human cancer. *Nat Genet* **41**: 521–523.

Velangi MR, Matheson EC, Morgan GJ, Jackson GH, Taylor PR, Hall AG, Irving JA (2004) DNA mismatch repair pathway defects in the pathogenesis and evolution of myeloma. *Carcinogenesis* **25**: 1795–1803.

Vermeulen W, Fousteri M (2013) Mammalian transcription-coupled excision repair. *Cold Spring Harb Perspect Biol* **5**: a012625.

Walters DK, Wu X, Tschumper RC, Arendt BK, Huddleston PM, Henderson KJ, Dispenzieri A, Jelinek DF (2011) Evidence for ongoing DNA damage in

multiple myeloma cells as revealed by constitutive phosphorylation of H2AX. *Leukemia* **25**: 1344–1353.

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.

Supplementary Information accompanies this paper on British Journal of Cancer website (<http://www.nature.com/bjc>)